Holen Sie sich die Stockscreener-App
131.10
2.48%
-3.33
Vorhandelsmarkt:
130.00
-1.10
-0.84%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$134.43
Offen:
$133.99
24-Stunden-Volumen:
6.26M
Relative Volume:
1.02
Marktkapitalisierung:
$162.77B
Einnahmen:
$29.79B
Nettoeinkommen (Verlust:
$9.22B
KGV:
17.84
EPS:
7.3494
Netto-Cashflow:
$10.23B
1W Leistung:
-2.43%
1M Leistung:
-0.42%
6M Leistung:
+5.45%
1J Leistung:
+19.10%
1-Tages-Spanne:
$130.53
$133.99
1-Wochen-Bereich:
$130.53
$137.20
52-Wochen-Spanne:
$104.46
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, AZN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
131.10 | 166.90B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,082.20 | 985.37B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
223.51 | 542.42B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
212.93 | 384.67B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
115.17 | 293.22B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
179.71 | 287.95B | 60.48B | 10.40B | 8.05B | 3.3297 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-11 | Bestätigt | Needham | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead Sciences Inc. stock underperforms Monday when compared to competitors - MarketWatch
RBC Capital maintains Gilead Sciences stock rating on HIV franchise outlook By Investing.com - Investing.com India
Gilead (GILD) to Showcase New Cancer Therapy Data - Yahoo Finance
RBC Capital maintains Gilead Sciences stock rating on HIV franchise outlook - Investing.com
MUFG Securities EMEA plc Sells 58,888 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Commonwealth of Pennsylvania Public School Empls Retrmt SYS Decreases Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead: 'Hold' On BIKTARVY Sales Growth And MM Drug Development Program (NASDAQ:GILD) - Seeking Alpha
Grandfield & Dodd LLC Sells 28,306 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Railway Pension Investments Ltd Has $171.75 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Koss Olinger Consulting LLC Sells 13,702 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Savant Capital LLC Has $3.32 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Norges Bank Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat
Eurizon Capital SGR S.p.A. Invests $117.43 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More - The Motley Fool
Gilead Sciences Inc. stock outperforms competitors despite losses on the day - MarketWatch
Gilead scraps lead arthritis drug from $405M MiroBio buyout in latest blow to BTLA agonist field - Fierce Biotech
13,211 Shares in Gilead Sciences, Inc. $GILD Acquired by SBI Okasan Asset Management Co.Ltd. - MarketBeat
United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Purchases 424,796 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
National Pension Service Reduces Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Ilmarinen Mutual Pension Insurance Co - MarketBeat
Intech Investment Management LLC Buys 48,622 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Fideuram Asset Management Ireland dac Buys Shares of 99,871 Gilead Sciences, Inc. $GILD - MarketBeat
Foundations Investment Advisors LLC Purchases 7,603 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
GILD Stock Price, Quote & Chart | GILEAD SCIENCES INC (NASDAQ:GILD) - ChartMill
Gilead (GILD) Wins FDA Approval for First HDV Treatment Hepcludex - Yahoo Finance
WHO identifies Ebola treatments, vaccines to be tested in trials amid outbreak - Reuters
Regeneron, Gilead therapies eyed as potential Ebola treatments by WHO - Seeking Alpha
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Wells Fargo Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $165 - Moomoo
Harbour Investments Inc. Boosts Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Geode Capital Management LLC Sells 232,984 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead boosts Assembly Biosciences (NASDAQ: ASMB) ownership to 25.1% of shares - Stock Titan
Gilead adds Assembly Biosciences (ASMB) shares through new stock grant - Stock Titan
Pharmacies Hit With Injunction In Gilead Counterfeit Drug Row - Law360
GILD: Promising Results for Livdelzi in Treating Primary Biliary Cholangitis - GuruFocus
Gilead liver drug Livdelzi normalizes key PBC marker in 2‑year study - Stock Titan
Flputnam Investment Management Co. Raises Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
User - The Chronicle-Journal
Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar) - Business Wire
Gilead wins hepatitis D drug approval as two Bay Area rivals line up their drugs - The Business Journals
Gilead Sciences Secures First FDA Approval For Hepcludex In Chronic Hepatitis Delta Virus Treatment - BioPharma APAC
Scotiabank Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $177 - Moomoo
Eukles Asset Management Cuts Position in Gilead Sciences, Inc. $GILD - MarketBeat
Allstate Corp Buys 47,838 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead's drug wins first-ever US approval for deadly liver infection - Reuters
Gilead Sciences (GILD) Acquires Tubulis for $3.15B to Expand Oncology Portfolio - Insider Monkey
GILD Scores FDA Win for HDV Drug, CHMP Backs Trodelvy - TradingView
Todd Asset Management LLC Increases Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Legal & General Group Plc Has $1.27 Billion Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Simplify Asset Management Inc. Lowers Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Life Cycle Investment Partners Ltd Takes $1.42 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):